利妥昔单抗与霉酚酸酯治疗间质性肺病（EVER-ILD）：一项随机对照试验的1年随访结果 - Suppr

Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial.

作者信息

Mansy Laurène, Caille Agnès, Reynaud-Gaubert Martine, Bermudez Julien, Bonniaud Philippe, Borie Raphael, Brillet Pierre-Yves, Cadranel Jacques, Court-Fortune Isabelle, Crestani Bruno, Debray Marie-Pierre, Duprez Mathilde, Guillaumot Anne, Hirschi-Santelmo Sandrine, Israel-Biet Dominique, Jouneau Stéphane, Juvin Karine, Kerjouan Mallorie, Mankikian Julie, Marquette Charles-Hugo, Naccache Jean-Marc, Nunes Hilario, Plantier Laurent, Prevot Grégoire, Quetant Sébastien, Traclet Julie, Valentin Victor, Uzunhan Yurdagul, Wémeau-Stervinou Lidwine, Cottin Vincent, Marchand-Adam Sylvain

机构信息

CIC, INSERM 1415, CHRU Tours, Tours, France.

Methods in Patients-Centered Outcomes and Health Research, INSERM UMR 1246, Nantes, France.

出版信息

Eur Respir J. 2024 Sep 12;64(3). doi: 10.1183/13993003.01368-2024. Print 2024 Sep.

DOI:10.1183/13993003.01368-2024

PMID:39231630

Abstract

摘要

相似文献

Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial.利妥昔单抗与霉酚酸酯治疗间质性肺病（EVER-ILD）：一项随机对照试验的1年随访结果

Eur Respir J. 2024 Sep 12;64(3). doi: 10.1183/13993003.01368-2024. Print 2024 Sep.

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.利妥昔单抗和霉酚酸酯联合治疗间质性肺病患者（EVER-ILD）：一项双盲、随机、安慰剂对照试验。

Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.02071-2022. Print 2023 Jun.

Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.利妥昔单抗和霉酚酸酯联合成功进行多靶点治疗抗黑色素瘤分化相关基因5抗体阳性且伴有临床无肌病性皮肌炎的快速进展性间质性肺病。

Int J Rheum Dis. 2017 Dec;20(12):2182-2185. doi: 10.1111/1756-185X.13136. Epub 2017 Jul 27.

Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.利妥昔单抗联合霉酚酸酯治疗系统性硬化症。单中心病例系列研究。

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):142-145. Epub 2018 Sep 30.

Management of systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关间质性肺疾病的管理。

Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592.

Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.霉酚酸酯治疗临床无肌病性皮肌炎患者的快速进展性间质性肺病。

Mod Rheumatol. 2014 Jul;24(4):694-6. doi: 10.3109/14397595.2013.874762. Epub 2014 Feb 7.

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.肌炎相关间质性肺病的硫唑嘌呤和霉酚酸酯长期治疗。

Chest. 2019 Nov;156(5):896-906. doi: 10.1016/j.chest.2019.05.023. Epub 2019 Jun 22.

Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.对来自EUSTAR数据库的系统性硬化症相关间质性肺病（SSc-ILD）患者使用托珠单抗、利妥昔单抗、霉酚酸酯和环磷酰胺有效性的事后比较。

Ann Rheum Dis. 2025 Apr;84(4):620-631. doi: 10.1016/j.ard.2025.01.014. Epub 2025 Feb 1.

Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.评估利妥昔单抗联合霉酚酸酯在一线免疫抑制治疗无应答的特发性间质性肺炎患者中的疗效和安全性（EVER-ILD）：一项双盲安慰剂对照随机试验。

Respir Med Res. 2020 Nov;78:100770. doi: 10.1016/j.resmer.2020.100770. Epub 2020 May 23.

Combining rituximab with mycophenolate for the treatment of interstitial lung disease.将利妥昔单抗与霉酚酸酯联合用于治疗间质性肺疾病。

Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.00614-2023. Print 2023 Jun.

引用本文的文献

Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.系统性硬化症相关间质性肺疾病的个性化医疗

Curr Treatm Opt Rheumatol. 2025 Dec;11(1). doi: 10.1007/s40674-024-00221-7. Epub 2025 Jan 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献